NAMI-A is a ruthenium-based drug characterized by the selective activity against tumor metastases. NAMI-A inhibits adhesion and migration.

NAMI-A can significantly affect tumor cells with metastatic ability. The half lifetime of NAMI-A elimination from the lungs is longer than for liver, kidney, and primary tumor. NAMI-A bound to collagen is active on tumor cells as shown in vitro by an invasion test, using a modified Boyden chamber and Matrigel, and it inhibits the matrix metallo-proteinases MMP-2 and MMP-9 at micromolar concentrations [1]. The ruthenium drug NAMI-A inhibits the adhesion and migration of colorectal cancer cells. NAMI-A decreases α5β1 integrin expression and FAK auto-phosphorylation on Tyr 397 [2].

201653-76-1

C8H15Cl4N4ORuS

458.18

H2O:8.28 mg/mL (18.07 mM),Need ultrasonic and warming
Powder: -20°C for 3 years
In solvent: -80°C for 2 years